YIH
ANTX icon

Y-Intercept (HK)’s AN2 Therapeutics ANTX Stock Holding History

Y-Intercept (HK)’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-14,040
Closed -$119K – 1034
2023
Q2 		$119K Buy
+14,040
New +$101K 0.01% 1046

Other funds holding ANTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Y-Intercept (HK)'s ANTX Position: Q3 2023 in Review

Y-Intercept (HK) sold out of AN2 Therapeutics (ANTX) in Q3 2023, closing a stake of 14,040 shares — an estimated $119K sold.

Y-Intercept (HK) first reported a position in ANTX in Q2 2023 and held it in 1 quarter. The position peaked at $119K in Q2 2023. 37 funds tracked by Wall St. Rank hold ANTX as of Q3 2023.

  • Y-Intercept (HK) reported no remaining AN2 Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Y-Intercept (HK) sold 14,040 AN2 Therapeutics shares in Q3 2023, an estimated $119K.
  • Y-Intercept (HK) first reported a position in AN2 Therapeutics in Q2 2023 and held it in 1 quarter.
  • Y-Intercept (HK)'s AN2 Therapeutics position peaked at $119K in Q2 2023.
  • 37 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q3 2023.

Based on Y-Intercept (HK)'s 13F filing for Q3 2023, filed 14 Nov 2023.